Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement was ...

Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in ...

selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and ...

The injunction, which was agreed upon on February 25, 2025, prohibits Parse Biosciences from manufacturing, using, selling, or offering to sell its planned ATAC and ATAC-Multiome Single Cell products.

I hope this message finds you well. I have a question, i.e., if I have s 10x Genomics Multiome (scRNA-seq and scATAC-seq jointly profiled from the same single cells) dataset, a snmC-seq dataset, and a ...

The injunction, which was agreed upon on February 25, 2025, prohibits Parse Biosciences from manufacturing, using, selling, or offering to sell its planned ATAC and ATAC-Multiome Single Cell products.

Using single-cell multi-omics technologies-including scRNA-seq, scATAC-seq, and single-cell multiome analyses-they characterized the transcriptional and epigenomic landscapes of HIV-1-infected CD4+ T ...